Association study between brain-derived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan

Authors

  • Kanako Itoh,

    1. Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan
    Search for more papers by this author
  • Kenji Hashimoto,

    Corresponding author
    1. Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan
    • Department of Psychiatry (K2), Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chiba 260-8670, Japan.
    Search for more papers by this author
  • Eiji Shimizu,

    1. Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan
    Search for more papers by this author
  • Yoshimoto Sekine,

    1. Department of Psychiatry and Neurology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Norio Ozaki,

    1. Department of Psychiatry and Psychobiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Toshiya Inada,

    1. Department of Psychiatry and Psychobiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Mutsuo Harano,

    1. Department of Neuropsychiatry, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Nakao Iwata,

    1. Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Tokutaro Komiyama,

    1. National Center Hospital for Mental, Nervous and Muscular Disorders, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Mitsuhiko Yamada,

    1. Karasuyama Hospital, Showa University School of Medicine, Tokyo, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Ichiro Sora,

    1. Division of Psychobiology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Kenji Nakata,

    1. Department of Neuropsychiatry, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Hiroshi Ujike,

    1. Department of Neuropsychiatry, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Masaomi Iyo

    1. Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author

Abstract

Several lines of evidence suggest that genetic factors might contribute to drug abuse vulnerability. Recent genomic scans for association demonstrated that the brain-derived neurotrophic factor (BDNF) gene was associated with drug abuse vulnerability. In this study, we analyzed association of two BDNF gene single nucleotide polymorphisms (SNPs), 132C > T (C270T named formerly) in the noncoding region of exon V and 196G > A (val66met) in the coding region of exon XIIIA, with methamphetamine (MAP) abuse in Japan. No significant differences were found in the frequency of the genotype or allele in these two SNPs between MAP abusers and controls (132C > T in exon V: genotype, P = 0.586, allele, P = 0.594; 196G > A (val66met) in exon XIIIA: genotype, P = 0.889, allele, P = 0.713). Furthermore, there was no difference between clinical parameters (e.g., prognosis psychosis, spontaneous relapse, or poly-substance abuse) and the two SNPs of BDNF gene. These results suggest that the two SNPs (132C > T in exon V and 196G>A (val66met) in exon XIIIA) of the BDNF gene may not be associated with Japanese MAP abusers. This article contains supplementary material, which may be viewed at the American Journal of Medical Genetics website at http://www.interscience.wiley.com/jpages/0148-7299:1/suppmat/index.html. © 2004 Wiley-Liss, Inc.

Ancillary